- Q1 2024 AIM ImmunoTech Inc Earnings Call TranscriptMay 16, 2024€0.364 (+0.55%)Earnings
- Q4 2023 AIM ImmunoTech Inc Earnings Call TranscriptApr 02, 2024€0.452 (+5.12%)Earnings
- AIM ImmunoTech Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Q2 2023 AIM ImmunoTech Inc Earnings Call TranscriptAug 15, 2023€0.57 (+7.55%)Earnings
- AIM ImmunoTech Inc Investor Summer Spotlight Series TranscriptJul 12, 2023
- Q1 2023 AIM ImmunoTech Inc Earnings Call TranscriptMay 16, 2023€0.372 (-6.53%)Earnings
- Q4 2022 AIM ImmunoTech Inc Earnings Call TranscriptApr 03, 2023€0.39 (+1.38%)Earnings
- AIM ImmunoTech Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- AIM ImmunoTech Inc at JTC Team Top Picks Virtual Investor Conference TranscriptJan 26, 2022
- AIM ImmunoTech Inc at SNN Network Virtual Conference TranscriptAug 03, 2020
- AIM ImmunoTech on Commercial Launch in Argentina for Chronic Fatigue and COVID-19 Clinical Trials- Corporate Analyst Meeting TranscriptJul 31, 2020
- CEO Roadshow Interview: Thomas Equels, CEO of AIM Immunotech Corporate Analyst Meeting TranscriptJun 24, 2020
- AIM ImmunoTech greenlit to import chronic fatigue syndrome drug into Argentina Corporate Analyst Meeting TranscriptJun 22, 2020
- AIM ImmunoTech Inc To Describe Their Approach and Progress with Ampligen to Combat COVID-19 TranscriptMay 28, 2020
- AIM ImmunoTech Inc at SNN Planet MicroCap Showcase TranscriptApr 22, 2020
AIM ImmunoTech Inc at JTC Team Top Picks Virtual Investor Conference Transcript
Good morning, everyone, and welcome to day two of the virtual investor event. My name is Jenene Thomas; I am CEO of JTC IR. And we're so happy to have everyone join us today. This is day two, and we still have tomorrow left as well. So for all of our participants, please visit our website at virtualinvestor.com for the latest schedule of presenting companies.
We are so thrilled to have Mr. Tom Equels on the presenting stage today. So we have AIM ImmunoTech; they're traded on NYSE American under the ticker AIM. Welcome, Tom.
Thank you very much, Jenene, and I want to thank all of the attendees for your interest in AIM ImmunoTech and the great work that we're doing. We are very excited about where we're at right now in terms of the opportunity to bring significant developments to bear in the development of our drug Ampligen, and we want to share that with you today.
Wonderful. Well, I'm excited to have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)